DelveInsight’s “Cryoglobulinemia- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Cryoglobulinemia, historical and forecasted epidemiology as well as the Cryoglobulinemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Cryoglobulinemia market report provides current treatment practices, emerging drugs, Cryoglobulinemia market share of the individual therapies, and current and forecasted Cryoglobulinemia market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Cryoglobulinemia treatment practices/algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Some of the key facts of the Cryoglobulinemia Market:
-
Cryoglobulins are proteins that precipitate from an individual’s serum or plasma at temperatures lower than 37°C. They can be a mixture of immunoglobulin (Ig) and complement components or immunoglobulins alone. These cryoglobulins deposit in medium and large-sized blood vessels throughout the body, causing endothelial injury and end-organ damage known as cryoglobulinemia. This activity describes the evaluation and management of cryoglobulinemia and highlights the role of the interprofessional team in improving care for patients with this condition.
Got queries? Click here to know more about the Cryoglobulinemia Market Landscape
Cryoglobulinemia Overview
Cryoglobulins are proteins that precipitate from an individual’s serum or plasma at temperatures lower than 37°C. They can be a mixture of immunoglobulin (Ig) and complement components or immunoglobulins alone. These cryoglobulins deposit in medium and large-sized blood vessels throughout the body, causing endothelial injury and end-organ damage known as cryoglobulinemia. Diagnosis of this entity should be suspected in patients presenting with skin ulcers, arthralgia, glomerulonephritis, neuropathy, and purpura. Brouet criteria classify cryoglobulinemia into three subgroups based on their immunoglobulin (Ig) composition.
Type I Cryoglobulinemia: It has monoclonal Igs, typically IgG or IgM, and develops in the setting of lymphoproliferative or hematologic disorders of B cell lineage (e.g., multiple myeloma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, or protein-secreting monoclonal gammopathies like monoclonal gammopathy of undetermined significance (MGUS).
Type II Cryoglobulinemia: Type I and II are mixed cryoglobulinemia and have polyclonal Igs associated with autoimmune diseases, malignancy, or infections, particularly hepatitis C virus (HCV) infection. Their constituent Ig is not a single monoclonal Ig. Cryoglobulins are composed of a mixture of a monoclonal IgM (or IgG or IgA) with rheumatoid factor (RF) activity and polyclonal Ig in type II cryoglobulinemia
Cryoglobulinemia Epidemiology Insights
-
According to the Muscular Dystrophy Association, Myasthenia gravis (MG) is an autoimmune disease that occurs when the immune system attacks the body’s own tissues. In MG, that attack interrupts the connection between nerve and muscle—the neuromuscular junction. MG is characterized by autoantibodies against the acetylcholine receptor (AChR-Ab) or against a receptor-associated protein called muscle-specific tyrosine kinase (MuSK-Ab).
-
In 2021, the total prevalent cases of gMG were the highest in the US, with approximately 40,000 cases, and lowest in Italy with approximately 8,800 cases.
-
There were approximately 13,500 males and 26,500 females affected by gMG in the United States in 2021 and it is estimated that the prevalence will increase and reach up to 15,500 and 30,300 in males and females by 2032.
Cryoglobulinemia Epidemiology Segmentation
-
Cryoglobulinemia is a rare condition and is clinically significant in about 1 in 100,000. Cryoglobulins have been identified in several situations, specifically, including 15% to 20% of HIV-infected individuals, 40 to 65 percent of Hepatitis C-infected patients, and approximately 64 percent of HIV/HepC coinfected individuals.
-
Patients with type 1 cryoglobulin are anywhere from 5% to 25% of the cases based on the currently available case series.
Cryoglobulinemia Market Outlook
The Cryoglobulinemia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cryoglobulinemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Cryoglobulinemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight
According to DelveInsight, the Cryoglobulinemia market in 7MM is expected to change in the study period 2019-2032.
Learn more by requesting for sample @ Cryoglobulinemia Market Trends
Cryoglobulinemia Key Companies
-
Gilead Sciences
-
And many others
Cryoglobulinemia Therapies
-
Drug: Harvoni
-
And many others
Table of Contents
-
Key Insights
-
Report Introduction
-
Executive Summary of Cryoglobulinemia
-
Disease Background and Overview
-
Epidemiology and patient population
-
Cryoglobulinemia Emerging Therapies
-
Cryoglobulinemia Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Cryoglobulinemia Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Click here to read more about Cryoglobulinemia Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com